Introduction: The coronavirus disease 2019 (COVID-19) pandemic caused by a novel coronavirus known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has expanded rapidly worldwide. The sudden occurrence of this pandemic of coronavirus disease 2019 (COVID-19) has affected significantly the health-care system all over the country and has developed an unusual menace for the therapeutic management of these at risk group of cancer patients. Materials and methods: This retrospective observational hospital based study was done on malignant cases. Real -time Polymerase Chain Reaction was performed for SARS COV- 2 in all these patients. Results: Among 164 patients, 58% patients were women and 42% were men. The majority of cases (31.7%) were in the 51-60 years of age group. Co-morbidities like hypertension, hypothyroidism, diabetes mellitus were found in 91% patients. Most of the breast cancer patients suffered from COVID-19 (20.12%), followed by esophageal cancer patients (10.98%). The period of COVID-19 positivity in different types of cancer patients ranged from first week to thirteenth week. On investigating the period of COVID-19 positivity in cancer patients with co morbidities, statistically significant difference were found. Discussion: Cancer patients are particularly at higher risk of getting infected with respiratory pathogens because of the immunosuppressive state. Cancer associated elements also appears to play a crucial role in prognosis of patients with cancer. Conclusion: Both patient and cancer-related factors has a remarkable part in the course of this disease. All these factors needs to be considered in development of COVID-19 preventative as well as therapeutic strategies in cancer patients to improve the patient care.